We have put together a collection of consensus documents covering various aspects of cystic fibrosis care. Read our online publications today.
Search result from the Trials Tracker
Study details
The purpose of this study is to find out whether GLPG2222, taken by mouth as tablet once a day, is safe, well-tolerated and effective in improving your signs and symptoms of cystic fibrosis. The study will also evaluate how the body takes in and breaks down the study drug (GLPG2222). The amount of drug in your blood will be measured at specific study visits after you start taking the drug. These measurements will show how quickly the drug is taken up by the body, how quickly it is broken down, when it reaches a steady level in the blood, and...
- Trials Tracker ID
- TT001766
- Age range
- 18 years and older
- Length of participation
- 6 - 10 weeks
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
This trial has been archived
Study details
Cystic fibrosis (CF) is a life-shortening genetic disease that damages many of the body’s organs, including the lungs, pancreas and digestive system. Cystic fibrosis related diabetes (CFRD) is the most common complication of CF, affecting 45-50% of adults. CFRD is different from type 1 and 2 diabetes and needs specialist dietary and clinical management. CFRD has a significant effect on nutrition, lung function and survival. The need to educate people with CFRD is important because, keeping blood glucose controlled results in improvements in nutrition, and reduces the development of long term complications from CFRD, including death. NICE recommends that everyone...
- Trials Tracker ID
- TT001761
- Age range
- 16 years and older
- Length of participation
- 2 days
- Trial status
- Closed with results
- Therapeutic approach
- Nutritional-GI
Search result from the Trials Tracker
Study details
This study focuses on the usage of the PAM-13 which is being used as one of the secondary outcome measures to evaluate the intervention we developed. While we would expect that people with higher patient activation scores or levels would have higher levels of adherence no such pattern could be discerned from an initial analysis of the pilot trial baseline data (WP 3.1, Arden et al., unpublished). This has led to the question of how patients with Cystic Fibrosis in the UK interpret and respond to the PAM-13. Given the limited existing evidence of the effectiveness of the PAM-13 in...
- Trials Tracker ID
- TT001756
- Age range
- 16 years and older
- Length of participation
- 1 day
- Trial status
- Closed with results
- Therapeutic approach
- Behavioural
Read the Association of Chartered Physiotherapists in Cystic Fibrosis' statement on the VEST.
Search result from the Trials Tracker
Study details
This is a randomized, placebo controlled, double-blinded study. 24 CF subjects will be assigned randomly to two groups, active drug or placebo. Three doses of FDL169 or placebo will be given 3 times a day for 28 days. The aim of this clinical study is to test how well CF subjects tolerate FDL169. In addition, the study will also test how subjects’ bodies absorb and digest FDL169 by measuring study subjects’ blood at specific intervals after taking the tablet orally.
- Trials Tracker ID
- TT001716
- Age range
- 18 years and older
- Length of participation
- 28 days
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
Search result from the Trials Tracker
Study details
Poor adherence is associated with poor clinical outcomes including distressing unscheduled hospitalisations. We have designed an intervention that will feedback adherence data to PWCF using chipped nebulisers displaying real time treatment use on smartphones and the website (CFHealthhub). Feedback is a powerful support to habit formation and the interventionist will use CFHealthHub and a behaviour change manual to support PWCF in building successful treatment habits. This work package follows on from a successful Pilot and Feasibility study that successfully met the recruitment target to deem the main RCT feasible. This was based on recruiting 64 PWCF over four months at...
- Trials Tracker ID
- TT001711
- Age range
- 16 years and older
- Length of participation
- 12 months
- Trial status
- Closed with results
- Therapeutic approach
- Behavioural
Search result from the Trials Tracker
Study details
The study drug, called RPL554, is a potential new inhaled drug that is being developed for the treatment of breathing and lung diseases, including cystic fibrosis. The study drug is a liquid that is breathed in using a device called a nebuliser, which is a commonly used device that turns a liquid into a fine mist that can then be inhaled into the lungs where it can then be taken into the body. Over 240 people have been given RPL554 in clinical studies so far. Two different formulations (how the drug is made up) have been tested in these studies...
- Trials Tracker ID
- TT001701
- Age range
- 18 years and older
- Length of participation
- 52 days
- Trial status
- Closed with results
- Therapeutic approach
- Anti-Inflammatory
Search result from the Trials Tracker
Study details
This is a Phase IIa, randomized, double-blind, placebo-controlled study to evaluate GLPG2222 in ivacaftor-treated subjects with Cystic Fibrosis (CF) with one F508del CFTR mutation and a second gating (class III) mutation. Up to 35 participants are planned to be included in the study for a minimum of 6 weeks and a maximum of 10 weeks. All participants will be at least 18 years of age and have cystic fibrosis with at least one copy of the F508del (Class II) mutation. This study will investigate whether treatment with the corrector GLPG2222 in patients heterozygous for F508del and a gating mutation who...
- Trials Tracker ID
- TT001681
- Age range
- 18 years and older
- Trial status
- Closed with results
- Therapeutic approach
- Restore CFTR Function
